Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany

Abstract Background Eptinezumab is a monoclonal antibody that targets calcitonin gene-related peptide (CGRP mAb) and is used for migraine prophylaxis. Efficacy data are mainly from clinical trials, real-world data are hardly available yet. Reimbursement policy in Germany leads to eptinezumab mainly...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Armin Scheffler, Pauline Wenzel, Merle Bendig, Astrid Gendolla, Jale Basten, Christoph Kleinschnitz, Michael Nsaka, Diana Lindner, Steffen Naegel, Philipp Burow, Robert Fleischmann, Dagny Holle
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-05-01
coleção:	The Journal of Headache and Pain
Assuntos:	Episodic migraine Chronic migraine Drug resistant Antibody switch
Acesso em linha:	https://doi.org/10.1186/s10194-024-01788-1
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!